vs
Liberty Broadband Corp（LBRDA）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$261.0M vs $207.3M），Liberty Broadband Corp净利率更高（146.7% vs -62.0%，领先208.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 6.1%），Liberty Broadband Corp自由现金流更多（$37.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.3%）
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LBRDA vs RARE — 直观对比
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.0M | $207.3M |
| 净利润 | $383.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 15.7% | -54.7% |
| 净利率 | 146.7% | -62.0% |
| 营收同比 | 6.1% | 25.9% |
| 净利润同比 | 96.4% | 3.5% |
| 每股收益（稀释后） | $2.68 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $207.3M | ||
| Q3 25 | — | $159.9M | ||
| Q2 25 | $261.0M | $166.5M | ||
| Q1 25 | $266.0M | $139.3M | ||
| Q4 24 | $263.0M | $164.6M | ||
| Q3 24 | $262.0M | $139.5M | ||
| Q2 24 | $246.0M | $147.0M | ||
| Q1 24 | $245.0M | $108.8M |
| Q4 25 | — | $-128.6M | ||
| Q3 25 | — | $-180.4M | ||
| Q2 25 | $383.0M | $-115.0M | ||
| Q1 25 | $268.0M | $-151.1M | ||
| Q4 24 | $291.0M | $-133.2M | ||
| Q3 24 | $142.0M | $-133.5M | ||
| Q2 24 | $195.0M | $-131.6M | ||
| Q1 24 | $241.0M | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | 15.7% | -64.8% | ||
| Q1 25 | 16.2% | -102.6% | ||
| Q4 24 | 4.9% | -74.3% | ||
| Q3 24 | 11.5% | -94.6% | ||
| Q2 24 | 8.5% | -79.1% | ||
| Q1 24 | 11.4% | -151.9% |
| Q4 25 | — | -62.0% | ||
| Q3 25 | — | -112.8% | ||
| Q2 25 | 146.7% | -69.0% | ||
| Q1 25 | 100.8% | -108.5% | ||
| Q4 24 | 110.6% | -80.9% | ||
| Q3 24 | 54.2% | -95.7% | ||
| Q2 24 | 79.3% | -89.5% | ||
| Q1 24 | 98.4% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | $2.68 | $-1.17 | ||
| Q1 25 | $1.87 | $-1.57 | ||
| Q4 24 | $2.04 | $-1.34 | ||
| Q3 24 | $0.99 | $-1.40 | ||
| Q2 24 | $1.36 | $-1.52 | ||
| Q1 24 | $1.69 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $421.0M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $10.4B | $-80.0M |
| 总资产 | $16.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | $180.0M | $176.3M | ||
| Q1 25 | $226.0M | $127.1M | ||
| Q4 24 | $163.0M | $174.0M | ||
| Q3 24 | $168.0M | $150.6M | ||
| Q2 24 | $73.0M | $480.7M | ||
| Q1 24 | $108.0M | $112.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $3.8B | — | ||
| Q4 24 | $3.8B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | — | ||
| Q1 24 | $3.6B | — |
| Q4 25 | — | $-80.0M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | $10.4B | $151.3M | ||
| Q1 25 | $10.1B | $144.2M | ||
| Q4 24 | $9.8B | $255.0M | ||
| Q3 24 | $9.5B | $346.8M | ||
| Q2 24 | $9.3B | $432.4M | ||
| Q1 24 | $9.1B | $140.3M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $16.6B | $1.3B | ||
| Q1 25 | $17.0B | $1.3B | ||
| Q4 24 | $16.7B | $1.5B | ||
| Q3 24 | $16.3B | $1.5B | ||
| Q2 24 | $16.0B | $1.6B | ||
| Q1 24 | $15.7B | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.38× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $91.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 14.2% | -48.6% |
| 资本支出强度资本支出/营收 | 20.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.24× | — |
| 过去12个月自由现金流最近4个季度 | $-49.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-99.8M | ||
| Q3 25 | — | $-91.4M | ||
| Q2 25 | $91.0M | $-108.3M | ||
| Q1 25 | $78.0M | $-166.5M | ||
| Q4 24 | $1.0M | $-79.3M | ||
| Q3 24 | $24.0M | $-67.0M | ||
| Q2 24 | $27.0M | $-77.0M | ||
| Q1 24 | $52.0M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | $37.0M | $-110.7M | ||
| Q1 25 | $13.0M | $-167.8M | ||
| Q4 24 | $-63.0M | $-79.5M | ||
| Q3 24 | $-36.0M | $-68.6M | ||
| Q2 24 | $-35.0M | $-79.0M | ||
| Q1 24 | $-9.0M | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | 14.2% | -66.5% | ||
| Q1 25 | 4.9% | -120.5% | ||
| Q4 24 | -24.0% | -48.3% | ||
| Q3 24 | -13.7% | -49.2% | ||
| Q2 24 | -14.2% | -53.7% | ||
| Q1 24 | -3.7% | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 20.7% | 1.5% | ||
| Q1 25 | 24.4% | 1.0% | ||
| Q4 24 | 24.3% | 0.1% | ||
| Q3 24 | 22.9% | 1.2% | ||
| Q2 24 | 25.2% | 1.4% | ||
| Q1 24 | 24.9% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LBRDA
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
